|
|
Article: Recent findings from F. Ziemssen and co-authors highlight research in macular degeneration therapy.(Report)
- Article from:
- Cancer Weekly
- Article date:
- July 7, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
New research, 'Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence,' is the subject of a report. "There is an active and controversial debate about the role of intravitreal bevacizumab versus approved drugs in the treatment of neovascular age-related macular degeneration (AMD). Because bevacizumab was available prior to the launch of ranibizumab, off-label use of the former became widespread and the cancer drug bevacizumab is the most commonly used medication in ophthalmology nowadays," researchers in Germany report (see also Macular Degeneration Therapy).
"This review considers every publication identified in ...
Related newspaper, magazine, and journal articles:
|
|
Article: U.S. FDA grants fast track review status for macular ...
Drug Week;
October 17, 2003 ;
700+ words
... ... with no classic and the minimally classic subfoveal choroidal neovascularization (CNV) due to age-related macular degeneration (AMD) patient populations. Under the FDA Modernization Act of 1997, designation as a fast track product means ...
|
|